BioCentury
ARTICLE | Cover Story

Gladstone's AD venture

July 14, 2011 7:00 AM UTC

The Gladstone Institute of Neurological Disease is launching a philanthropically funded translational research center to aid the preclinical development of Alzheimer's disease candidates emerging from the institute's research. The center hopes to pursue AD targets and mechanisms that go beyond the usual suspects like b-amyloid and TAU protein aggregation.

Gladstone's internal pipeline includes at least two new AD compounds-one handed back by Merck & Co. Inc. after a recently terminated co-development deal and the other a novel neuroprotective agent...